News ArticleBiocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Unaudited financial results show revenue of Rs. 14,105 million for half-year ended September 30, 2026; Dr. Mandar Ghatnekar resigns as CTO effective December 31, 2026
Biocon Limited announced unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026, reporting Rs. 1,439 million profit for the half-year. The company also disclosed the resignation of CTO Dr. Mandar Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO from January 1, 2027.
Biocon Limited
Financial Results
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
For the half-year ended September 30, 2026, Biocon recorded revenue from operations at Rs. 12,550 million and total income of Rs. 14,105 million, compared to Rs. 11,204 million and Rs. 13,155 million respectively for the previous half-year.
Expenses for the half-year totaled Rs. 12,208 million, including costs of materials consumed, employee benefits, finance costs, and depreciation, among others.
Profit before tax stood at Rs. 1,897 million for the half-year period, resulting in a profit after tax of Rs. 1,439 million.
Earnings per share for the half-year were Rs. 0.88 on a face value of Rs. 5 each.
In senior management updates, Dr. Mandar Ghatnekar resigned as Chief Technology Officer effective December 31, 2026. Mukesh Rathi, with over 27 years of experience in digital transformation and technology leadership, was appointed CTO effective January 1, 2027.
Highlights
- Profit after tax of Rs. 1,439 million for half-year ended September 30, 2026
- Revenue from operations reached Rs. 12,550 million in H1 FY2026-27
- Earnings per share at Rs. 0.88 for the half-year period
- CTO Dr. Mandar Ghatnekar to resign effective December 31, 2026
- Mukesh Rathi appointed as new CTO starting January 1, 2027, bringing extensive digital and technology leadership experience
Key Data Snapshot
Financial performance
- Biocon reported total income of Rs. 14,105 million for the half-year ended September 30, 2026.
- Expenses totaled Rs. 12,208 million including materials, employee benefits, finance costs, and depreciation.
- Profit before tax was Rs. 1,897 million, and profit after tax was Rs. 1,439 million for the period.
- Basic and diluted earnings per share were both Rs. 0.88 for the half-year.
Management commentary
- Dr. Mandar Shrikant Ghatnekar resigned as Chief Technology Officer effective December 31, 2026.
- Mr. Mukesh Rathi, formerly Group Chief Digital Officer at Hinduja Group and senior technology leader at Dr. Reddy’s Laboratories, appointed CTO effective January 1, 2027.
- Mr. Rathi brings 27 years of experience in digital transformation, AI-led innovation, and technology management.
Regulatory and governance context
- Financial results prepared as per Indian Accounting Standards (Ind-AS).
- Results for quarter and half-year ended September 30, 2026, are unaudited and subject to limited review.
- Management changes disclosed per SEBI Listing Regulations and relevant circulars.
Highlights
- Profit after tax of Rs. 1,439 million for half-year ended September 30, 2026
- Revenue from operations reached Rs. 12,550 million in H1 FY2026-27
- Earnings per share at Rs. 0.88 for the half-year period
- CTO Dr. Mandar Ghatnekar to resign effective December 31, 2026
- Mukesh Rathi appointed as new CTO starting January 1, 2027, bringing extensive digital and technology leadership experience
Disclosures
- SEBI Listing Regulations 2015 - Regulations 30 and 33
- SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Zydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
Clean Max Enviro Energy Solutions Plans INR 3000 Crore Debenture Issue and Sets Up IFSC Subsidiary in GIFT City
Clean Max Enviro Energy Solutions Limited announced a plan to raise up to INR 30,00,00,00,000 (INR 3000 crore) through issuance of listed, rated, redeemable non-convertible debentures via private placement. The debentures are to be listed on the Wholesale Debt Market segment of BSE Limited and/or NSE Limited. The company also approved incorporation of a wholly owned subsidiary in the International Financial Services Centre (IFSC) in GIFT City, Gujarat. Additionally, the company released its unaudited standalone and consolidated financial results for the quarter and half year ended September 30
Read Full Story
